Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment

BACKGROUND: We retrospectively analysed the efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with renal impairment. METHODS: Patients were divided into two groups by an estimated glomerular filtration rate (eGFR) cut-off of 45 mL/min/1.73 m(2). Background factors consi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatsugami, Katsunori, Oya, Mototsugu, Kabu, Koki, Akaza, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922406/
https://www.ncbi.nlm.nih.gov/pubmed/29721212
http://dx.doi.org/10.18632/oncotarget.24779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922406/
https://www.ncbi.nlm.nih.gov/pubmed/29721212
http://dx.doi.org/10.18632/oncotarget.24779

Ejemplares similares